(lp0
S'Galectin Therapeutics Inc. Announces Pricing of Public Offering of 1159445 ... Business Wire  - Mar 23, 2012 NEWTON, Mass.----Galectin Therapeutics Inc.  today announced the pricing of an underwritten public offering of 1,159,445 units at a price to the public of $9.00 per unit, with each unit consisting of two common voting&nbsp;...'
p1
aS'GALECTIN THERAPEUTICS INC.  Files An 8-K Entry into a Material ... Market Exclusive - Dec 29, 2016 Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer.'
p2
aS'analysts Recommendations: Galectin Therapeutics, Inc.  News Oracle - Feb 7, 2017 Galectin Therapeutics, Inc.  will report its next earnings on Mar 13 - Mar 17 . The company reported the earnings of $-0.19/Share in the last quarter where the estimated EPS by analysts was $-0.22/share. The difference between the&nbsp;...Galectin Therapeutics to Present at BIO CEO &amp; Investor Conference - PharmiWeb.com '
p3
aS'Investor Notebook: Focusing in on Shares of Galectin Therapeutics Inc  Rives Journal - Feb 8, 2017 Galectin Therapeutics Inc  currently has a 14-day Commodity Channel Index  of 127.7. Despite the name, CCI can be used on other investment tools such as stocks.'
p4
aS'Gainers &amp; Losers Of The Day: EYES, SGNL, NEOT, DMTX, MBRX... Nasdaq - Feb 8, 2017 Non-transferable subscription rights to purchase units, composed of a share of Second Sight common stock and a five-year warrant to purchase an additional share of common stock, will be issued in the offering.'
p5
aS'Gainers &amp; Losers Of The Day: ZSAN, EVOK, ARDX, EARS, NEOT... Nasdaq - Feb 16, 2017 Recent event: On Feb.13, the company announced that its pivotal phase III efficacy study of M207 in migraine met endpoints.'
p6
aS'Allergan to buy Tobira in push for fatty liver disease drugs Reuters - Sep 20, 2016 Botox maker Allergan Plc, in its third acquisition this month, said it would pay up to $1.7 billion for Tobira Therapeutics Inc to get a leg up in the race to develop therapies for NASH, an incurable fatty liver disease closely linked to obesity. Just ...'
p7
aS"Profil Institute Unites Leading Experts In Biomarker Discovery And Clinical ... Clinical Leader - Oct 29, 2015 Profil Institute is partnering with KineMed, Inc., a drug discovery and development company, and Dr. Rohit Loomba, founding director of UC San Diego's NAFLD Translational Research Unit and founder and principal investigator of the San Diego Integrated&nbsp;..."
p8
aS"Gainers &amp; Losers Of The Day: PULM, AQB, GALE, PETX, KTOV... RTT News - Feb 7, 2017 The company's lead compound is Emricasan, for the treatment of patients with chronic liver disease. A phase IIb trial of Emricasan in NASH cirrhosis patients, dubbed ENCORE-LF, is expected to be initiated in the second half of this year."
p9
aS'Pipeline Insights on Nonalcoholic Steatohepatitis Market MarketWatch - Sep 12, 2016 Companies discussed in this Non-Alcoholic Steatohepatitis Pipeline Review, H2 2016 report include Akarna Therapeutics Ltd., AlbireoPharma, Alnylam Pharmaceuticals, Inc., Amunix Operating Inc., Aquinox Pharmaceuticals Inc., Arisaph Pharmaceuticals, Inc ...'
p10
a.